Creative Planning’s Amylyx Pharmaceuticals AMLX Stock Holding History

Creative Planning’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$249K	Buy	+17,883	New	+$252K	﹤0.01%	3574

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Creative Planning's AMLX Position: Q1 2026 in Review

Creative Planning opened a new position in Amylyx Pharmaceuticals (AMLX) in Q1 2026: 17,883 shares worth $249K. The stake represents ﹤0.01% of the portfolio and ranks #3574 among its holdings.

171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

Creative Planning held 17,883 shares of Amylyx Pharmaceuticals worth $249K as of Q1 2026.
Amylyx Pharmaceuticals was a new Creative Planning position in Q1 2026.
Amylyx Pharmaceuticals made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #3574 holding.
171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.